Advertisement: EY Mid banner
Advertisement: China mid banner
Advertisement: Simpsons Creative
Barr Ellison Solicitors – commercial property
Advertisement: Kao Data Centre mid banner
Advertisement: Cambridge Network
Advertisement: EBCam mid banner
ARM Innovation Hub
RealVNC mid banner careers
RealVNC mid-banner general
Mid banner advertisement: BDO
Advertisement: RSM
Advertisement: Mogrify
23 July, 2020 - 12:29 By Tony Quested

CMR Surgical bridges Gulf with Middle East tie-up

Cambridge unicorn business CMR Surgical has engineered a potentially lucrative new market in the Gulf for its Versius robotic arm for keyhole surgery.

CMR Surgical reveals in a mid-year trading update that it has experienced a strong start to 2020 with new installations and orders in markets including the UK, India, Italy and France.

As part of its accelerating global rollout, CMR has formed a partnership with Gulf Drug – a medical equipment supplier in the United Arab Emirates – to take Versius to this strategically important region, increasing its commercial presence across Asia and the Middle East.

Strong progress has been made as part of the Versius clinical programme, with over 600 clinical cases successfully completed across gynaecology, upper GI, urology and colorectal surgery.

The clinical cases are being collected in the CMR clinical registry providing a growing wealth of data supporting the use of Versius worldwide.

Despite the COVID-19 pandemic and allied restrictions the company says manufacturing and new product development has been maintained at normal capacity.

CMR has worked closely with customers to support surgeons and hospitals during the pandemic. It says hospitals are now starting to increase elective procedures and CMR is focusing on supporting existing customers to deliver surgical care, with further new installations expected in the coming months.

Chief executive Per Vegard Nerseth, said: “We have seen continued strong demand for Versius. We will spend the second half of 2020 accelerating the global roll-out of Versius, so that we can bring minimal access surgery to everyone who needs it.”

He said the company’s cash position remained strong following the £195 million Series C financing round, ensuring that the business was in a robust financial position as it rolled out Versius into new markets.

Newsletter Subscription

Stay informed of the latest news and features